Multidisciplinary Journal of Science and Technology

CLINICAL AND IMMUNOGENETIC FOUNDATIONS FOR EARLY PREDICTION OF DECOMPENSATION PHENOTYPES IN LIVER CIRRHOSIS OF DIFFERENT ETIOLOGIES

Boburjon Abduqoxxorovich Rasulov

Assistant, Department of Pharmacology, Clinical Pharmacology and Medical Biotechnologies, Andijan State Medical Institute, Andijan, Uzbekistan

Jasurbek Ravzatov

PhD, Associate Professor, Department of Family Physician Training, Andijan State Medical Institute, Andijan, Uzbekistan

Keywords: liver cirrhosis, decompensation phenotypes, ascites, variceal bleeding, spontaneous bacterial peritonitis, hepatic encephalopathy, IL-23R, IL-17A, IL-17F, IL-6, clinical-genetic prognosis.

---

Abstract

Liver cirrhosis remains one of the leading causes of disability and mortality worldwide, including in Uzbekistan. The clinical severity of cirrhosis is determined not merely by the presence of cirrhotic transformation itself, but also by the development of decompensation phenotypes, including ascites, bleeding from esophageal varices, spontaneous bacterial peritonitis, and hepatic encephalopathy. In recent years, increasing attention has been paid to the role of the Th17/IL-23/IL-17 inflammatory axis and the IL-6 cascade in the pathogenesis of cirrhosis, particularly in relation to fibrosis progression, portal hypertension, disruption of the gut-liver immune axis, and infectious complications. This review systematically analyzes the role of clinical, immunological, and genetic factors in the early prediction of decompensation phenotypes in liver cirrhosis of different etiologies. Particular attention is given to the association of IL-23R, IL-17A, IL-17F, and IL-6 gene polymorphisms with disease course, decompensation phenotypes, and clinical-biochemical parameters. In addition, the scientific and practical prospects of integrating clinical-genetic risk stratification alongside conventional tools such as the Child-Pugh score are discussed.

---

References

1. Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. Portal hypertension and gastrointestinal bleeding. Semin Liver Dis. 2008;28(1):3–25. doi:10.1055/s-2008-1040318.

2. Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021;398(10308):1359–1376. doi:10.1016/S0140-6736(21)01374-X.

3. Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, et al. Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60(6):1310–1324. doi:10.1016/j.jhep.2014.01.024.

4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–460. doi:10.1016/j.jhep.2018.03.024.

5. Koyama Y, Brenner DA. Liver inflammation and fibrosis. J Clin Invest. 2017;127(1):55–64. doi:10.1172/JCI88881.

6. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011;141(5):1572–1585. doi:10.1053/j.gastro.2011.09.002.

7. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–1846. doi:10.1002/hep.24001.

8. Sun HQ, Zhang JY, Zhang H, Zou ZS, Wang FS, Jia JH. Increased Th17 cells contribute to disease progression in patients with HBV-associated liver cirrhosis. J Viral Hepat. 2012;19(6):396–403. doi:10.1111/j.1365-2893.2011.01561.x.

9. Tan Z, Qian X, Jiang R, Liu Q, Wang Y, Chen C, et al. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol. 2013;191(4):1835–1844. doi:10.4049/jimmunol.1203013.

10. Paquissi FC. Immunity and fibrogenesis: The role of the Th17/IL-17 axis in HBV and HCV-induced chronic hepatitis and progression to cirrhosis. Front Immunol. 2017;8:1195. doi:10.3389/fimmu.2017.01195.

11. Hammerich L, Heymann F, Tacke F. Role of IL-17 and Th17 cells in liver diseases. Clin Dev Immunol. 2011;2011:345803. doi:10.1155/2011/345803.

12. Beringer A, Noack M, Miossec P. IL-17 in chronic inflammation: From discovery to targeting. Trends Mol Med. 2016;22(3):230–241. doi:10.1016/j.molmed.2016.01.001.

13. Beringer A, Noack M, Miossec P. IL-17 and IL-17-producing cells in liver diseases, with focus on autoimmune liver diseases. Autoimmun Rev. 2018;17(12):1170–1176. doi:10.1016/j.autrev.2018.06.007.

14. Xia C, Lou G, Ye B, Chen F, Chen Z, Liu Y, et al. Genetic polymorphisms of interleukin-6 influence the development of hepatitis B virus-related liver cirrhosis in the Han Chinese population. Infect Genet Evol. 2020;84:104331. doi:10.1016/j.meegid.2020.104331.

15. Peng Q, Qin X, He Y, Li X, Wang Y, Li W, et al. Correlation between interleukin-23 receptor gene polymorphisms and hepatitis B virus infection in patients. Mol Med Rep. 2013;7(2):613–620. doi:10.3892/mmr.2013.1558.

16. Labib HA, Ahmed HS, Shalaby SM, Wahab EA. Genetic polymorphism of IL-23R influences susceptibility to HCV-related hepatocellular carcinoma. Cancer Genet. 2015;208(3):111–116. doi:10.1016/j.cancergen.2014.12.003.

17. Xiao S, Zhou L, Li J, et al. Gene polymorphisms of inflammatory factors in liver cirrhosis. Front Genet. 2023;14:1140427. doi:10.3389/fgene.2023.1140427.

18. Fortea JI, Fernández-Mena C, Puerto M, et al. Cirrhosis, a global and challenging disease. Int J Mol Sci. 2022;23(18):10664. doi:10.3390/ijms231810664.